Drug Candidates

3 candidates mapped to SDH-deficient disease pathways

All (15)established (4)clinical trial (2)preclinical (6)theoretical (3)
Olaparib

Lynparza

theoretical

PARP inhibitor

Oxidative Stress Ros
Evidence Score
45
FDA Approved
Panobinostat

Farydak

theoretical

Pan-HDAC inhibitor

Epigenetic Dysregulation
Evidence Score
30
FDA Approved
Enasidenib

Idhifa

theoretical

IDH2 inhibitor

Epigenetic Dysregulation
Evidence Score
28
FDA Approved